P/01
Immune-privileged
Characterised as immune-privileged with immunomodulatory behaviour — the property that makes an allogeneic, off-the-shelf model plausible at all.
Now accepting provider clinics
The youngest cell
in regenerative medicine.
Every other regenerative source starts at birth or later. Infinity Cell begins at the earliest ethical point in human development — a pre-implantation cell that is immune-privileged, chromosomally stable, and effectively limitless in expansion.
Cellular age at source
Day 0–14
Platform affiliations, collaborators & scientific advisory network
Alliance for Regenerative Medicine
The Wistar Institute
Advanced Regenerative Manufacturing Institute
Pluristyx
Intl. Society for Extracellular Vesicles
Stemmatters
Biotechnology Innovation Organization
Kaohsiung Medical University Hospital
JLABS
PACT
0+
Granted patents worldwide
0
Distinct patent families
0+
Differentiated lineages demonstrated
0
Embryos used or destroyed
01 — Cellular age
Every regenerative source has an age.
Every regenerative source has an age.
Ours is the lowest available.
Regenerative capacity is not evenly distributed across cell sources. A cell harvested from a 58-year-old patient carries 58 years of replicative and epigenetic history. Cord and placental tissue reset that clock to birth. Infinity Cell resets it further — to the first two weeks of human development, before implantation.
Infinity Cell
Infinity Cell (hTSC)
Day 0–14 · pre-implantation
02 — Biological profile
Six properties that rarely occur together
Most cell sources force a trade-off — potency against safety, scale against consistency, availability against ethics. The trophoblast lineage is unusual in how few of those trade-offs it requires.
P/02
Chromosomally stable
Karyotypically stable through expansion, rather than accumulating the abnormalities that often emerge in extended culture. Karyotype stability is what has been characterised — it is not a tumorigenicity finding.
P/03
Ethically unambiguous
Derived from non-viable tubal ectopic pregnancy tissue that could never result in a birth. No embryo is created or destroyed, and no viable pregnancy is affected.
P/04
Scales without drift
High expansion capacity from a single characterised master source — so lot 900 can be built to match lot 1, rather than depending on a new donor each time.
P/05
Multi-lineage
Differentiation has been demonstrated toward NK, chondrogenic, osteogenic, adipogenic, neural, pancreatic and hepatic lineages, plus secretome production.
P/06
Protected
54 granted patents and 46 pending across 12 families, as reported by Accelerated Biosciences (2026-07). This is not a commodity input that any competitor can source next quarter.
03 — Direct comparison
How it reads against what your clinic uses today
| Attribute | Infinity Cell | Umbilical cord | Adipose | Bone marrow |
|---|---|---|---|---|
| Biological age at source | Day 0–14 | ≈ 40 weeks | Donor age | Donor age |
| Immune-privileged profile | Characterised | Partial | Autologous only | Autologous only |
| Lot-to-lot consistency | Single master source | Donor-dependent | Patient-dependent | Patient-dependent |
| Harvest procedure required | None | None | Liposuction | Marrow aspiration |
| Expansion capacity | Very high | Moderate | Limited | Most limited |
| Ethical position | Non-viable ectopic tissue | Post-birth donation | Patient tissue | Patient tissue |
| Composition-of-matter IP | 54 patents | Commodity | Commodity | Commodity |
Comparison of source-class characteristics as generally described in the published literature. Regulatory classification and permitted clinical use vary by jurisdiction and by product format.
04 — Differentiation
One source. Many destinations.
Select a lineage to see where the research currently stands.
Status
Select a lineage
05 — Global footprint
See the published research
Studied across four continents
Trophoblast-lineage research is not a single-laboratory curiosity. Work spans discovery institutions in Asia, research institutes and manufacturing partners in North America, and development partners in Europe — with findings published in peer-reviewed journals indexed by the U.S. National Library of Medicine.
Region
06 — Provider programme
What a provider clinic receives
Full characterisation package
Certificate of analysis, identity and viability data, sterility and pathogen screening results, and lot traceability for every unit received.
Protocol & handling training
Structured onboarding covering cold chain, storage, preparation and documentation — delivered before your first shipment, not after.
A named scientific liaison
A single point of contact who knows the platform and can answer a clinician's question properly — not a support queue.
Patient education materials
Accurate, claim-controlled explainers your team can hand a patient — written to inform, not to oversell.
Regulatory documentation
The source, manufacturing and classification documentation your compliance review will ask for, supplied up front.
Territory consideration
Provider numbers are deliberately limited by region. Early applicants are reviewed for territory standing first.